Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in adolescents and adults with fragile X syndrome (FXS)
Epistemonikos ID: 1b105d2d497828cc9b57d1f0b54586702120c143
First added on: May 06, 2024